Outlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Up 139.5% in May

Share on StockTwits

Outlook Therapeutics, Inc. (NASDAQ:OTLK) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 2,211,700 shares, an increase of 139.5% from the April 30th total of 923,500 shares. Based on an average daily trading volume, of 4,730,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 91.8% of the company’s shares are sold short.

OTLK stock traded down $0.02 on Wednesday, hitting $2.15. 162,100 shares of the company’s stock traded hands, compared to its average volume of 2,460,027. The firm has a market cap of $57.83 million, a PE ratio of -0.21 and a beta of -0.86. Outlook Therapeutics has a 1-year low of $0.85 and a 1-year high of $10.96. The stock’s fifty day moving average is $2.25.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.08. The firm had revenue of $0.64 million during the quarter. Equities analysts anticipate that Outlook Therapeutics will post -1.95 earnings per share for the current fiscal year.

OTLK has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of XPO Logistics from a “strong sell” rating to a “sell” rating in a report on Thursday, April 4th. CIBC restated a “hold” rating and issued a $3.00 target price on shares of Information Services Group in a research report on Thursday, May 16th. Oppenheimer began coverage on shares of Outlook Therapeutics in a research note on Thursday, May 16th. They issued an “outperform” rating and a $12.00 price target for the company. Finally, Ascendiant Capital Markets began coverage on shares of Graham in a research note on Monday, April 22nd. They issued a “buy” rating and a $1.59 price target for the company.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Recommended Story: Why do companies pay special dividends?

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.